BACKGROUND: Approximately 10-15% of all breast tumors are triple-negative breast cancer (TNBC). TNBC have a higher risk of relapse and distant metastases compared to other subtypes. The optimal systemic management of TNBC according to national and international guidelines is discussed herein. SUMMARY: Anthracycline/taxane-based chemotherapy for patients with TNBC either in the neoadjuvant (NACT) or the adjuvant setting is considered standard of care. Exceptions are small tumors and a low-risk histology, in which chemotherapy can be spared. Dose-dense therapy is more effective in preventing recurrence and increasing survival. The use of nab-paclitaxel instead of a solvent-based taxane can lead to higher pathological complete response (pCR) rates and better outcomes. Platinum agents are effective in increasing pCR when added to anthracycline/taxane-based chemotherapy at the cost of increased toxicity. Long-term outcome data are lacking. In patients without a pCR, capecitabine leads to improved outcomes. KEY MESSAGES: The standard treatment approach of TNBC is anthracycline/taxane-based chemotherapy, preferably within the NACT setting. Dose-dense schedules as well as platinum should be considered in the NACT setting. For patients without a pCR, capecitabine is an option to improve the outcome. The role of nab-paclitaxel is under debate. In case of immunogenic tumors, checkpoint inhibitors are promising new agents that merit further investigation.
BACKGROUND: Approximately 10-15% of all breast tumors are triple-negative breast cancer (TNBC). TNBC have a higher risk of relapse and distant metastases compared to other subtypes. The optimal systemic management of TNBC according to national and international guidelines is discussed herein. SUMMARY: Anthracycline/taxane-based chemotherapy for patients with TNBC either in the neoadjuvant (NACT) or the adjuvant setting is considered standard of care. Exceptions are small tumors and a low-risk histology, in which chemotherapy can be spared. Dose-dense therapy is more effective in preventing recurrence and increasing survival. The use of nab-paclitaxel instead of a solvent-based taxane can lead to higher pathological complete response (pCR) rates and better outcomes. Platinum agents are effective in increasing pCR when added to anthracycline/taxane-based chemotherapy at the cost of increased toxicity. Long-term outcome data are lacking. In patients without a pCR, capecitabine leads to improved outcomes. KEY MESSAGES: The standard treatment approach of TNBC is anthracycline/taxane-based chemotherapy, preferably within the NACT setting. Dose-dense schedules as well as platinum should be considered in the NACT setting. For patients without a pCR, capecitabine is an option to improve the outcome. The role of nab-paclitaxel is under debate. In case of immunogenic tumors, checkpoint inhibitors are promising new agents that merit further investigation.
Authors: Rebecca Dent; Maureen Trudeau; Kathleen I Pritchard; Wedad M Hanna; Harriet K Kahn; Carol A Sawka; Lavina A Lickley; Ellen Rawlinson; Ping Sun; Steven A Narod Journal: Clin Cancer Res Date: 2007-08-01 Impact factor: 12.531
Authors: T Byrski; T Huzarski; R Dent; E Marczyk; M Jasiowka; J Gronwald; J Jakubowicz; C Cybulski; R Wisniowski; D Godlewski; J Lubinski; S A Narod Journal: Breast Cancer Res Treat Date: 2014-08-17 Impact factor: 4.872
Authors: Carsten Denkert; Gunter von Minckwitz; Jan C Brase; Bruno V Sinn; Stephan Gade; Ralf Kronenwett; Berit M Pfitzner; Christoph Salat; Sherene Loi; Wolfgang D Schmitt; Christian Schem; Karin Fisch; Silvia Darb-Esfahani; Keyur Mehta; Christos Sotiriou; Stephan Wienert; Peter Klare; Fabrice André; Frederick Klauschen; Jens-Uwe Blohmer; Kristin Krappmann; Marcus Schmidt; Hans Tesch; Sherko Kümmel; Peter Sinn; Christian Jackisch; Manfred Dietel; Toralf Reimer; Michael Untch; Sibylle Loibl Journal: J Clin Oncol Date: 2014-12-22 Impact factor: 44.544
Authors: Donald A Berry; Constance Cirrincione; I Craig Henderson; Marc L Citron; Daniel R Budman; Lori J Goldstein; Silvana Martino; Edith A Perez; Hyman B Muss; Larry Norton; Clifford Hudis; Eric P Winer Journal: JAMA Date: 2006-04-12 Impact factor: 56.272
Authors: Nancy U Lin; Ann Vanderplas; Melissa E Hughes; Richard L Theriault; Stephen B Edge; Yu-Ning Wong; Douglas W Blayney; Joyce C Niland; Eric P Winer; Jane C Weeks Journal: Cancer Date: 2012-04-27 Impact factor: 6.860
Authors: Patricia Cortazar; Lijun Zhang; Michael Untch; Keyur Mehta; Joseph P Costantino; Norman Wolmark; Hervé Bonnefoi; David Cameron; Luca Gianni; Pinuccia Valagussa; Sandra M Swain; Tatiana Prowell; Sibylle Loibl; D Lawrence Wickerham; Jan Bogaerts; Jose Baselga; Charles Perou; Gideon Blumenthal; Jens Blohmer; Eleftherios P Mamounas; Jonas Bergh; Vladimir Semiglazov; Robert Justice; Holger Eidtmann; Soonmyung Paik; Martine Piccart; Rajeshwari Sridhara; Peter A Fasching; Leen Slaets; Shenghui Tang; Bernd Gerber; Charles E Geyer; Richard Pazdur; Nina Ditsch; Priya Rastogi; Wolfgang Eiermann; Gunter von Minckwitz Journal: Lancet Date: 2014-02-14 Impact factor: 79.321
Authors: S Loibl; K E Weber; K M Timms; E P Elkin; E Hahnen; P A Fasching; B Lederer; C Denkert; A Schneeweiss; S Braun; C T Salat; M Rezai; J U Blohmer; D M Zahm; C Jackisch; B Gerber; P Klare; S Kümmel; C Schem; S Paepke; R Schmutzler; K Rhiem; S Penn; J Reid; V Nekljudova; A-R Hartman; G von Minckwitz; M Untch Journal: Ann Oncol Date: 2018-12-01 Impact factor: 32.976
Authors: Seifeddine Ben Hammouda; Nihed Abdessayed; Nouha Ben Abdeljelil; Hajer Hanchi; Dorra H Mida; Moncef Mokni Journal: Pan Afr Med J Date: 2022-05-12